NeoGenomics, Inc. (NEO): Price and Financial Metrics
NeoGenomics, Inc. (NEO)
Today's Latest Price: $27.01 USD
Updated Apr 1 10:30am
Add NEO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
NEO Stock Summary
- NEO's current price/earnings ratio is 354.2, which is higher than 99.02% of US stocks with positive earnings.
- Price to trailing twelve month operating cash flow for NEO is currently 121.34, higher than 98.02% of US stocks with positive operating cash flow.
- Revenue growth over the past 12 months for Neogenomics Inc comes in at 47.73%, a number that bests 88.79% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Neogenomics Inc are CRY, MMSI, BYFC, INFU, and ENR.
- Visit NEO's SEC page to see the company's official filings. To visit the company's web site, go to www.neogenomics.com.
NEO Stock Price Chart More Charts
NEO Price/Volume Stats
| Current price | $27.01 | 52-week high | $34.97 |
| Prev. close | $27.61 | 52-week low | $18.52 |
| Day low | $26.50 | Volume | 69,633 |
| Day high | $27.69 | Avg. volume | 957,164 |
| 50-day MA | $29.70 | Dividend yield | N/A |
| 200-day MA | $25.57 | Market Cap | 2.83B |
NeoGenomics, Inc. (NEO) Company Bio
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company was founded in 2001 and is based in Fort Myers, Florida.
NEO Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $27.01 | $0.26 | -99% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Neogenomics Inc. To summarize, we found that Neogenomics Inc ranked in the 3th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Neogenomics Inc, consider:
- The compound growth rate in the free cash flow of Neogenomics Inc over the past 5.59 years is -0.01%; that's better than only 21.41% of cash flow producing equities in the Healthcare sector, where it is classified.
- The business' balance sheet reveals debt to be 4% of the company's capital (with equity being the remaining amount). Approximately only 11.92% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- Neogenomics Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -99% |
| 1% | -99% |
| 2% | -99% |
| 3% | -99% |
| 4% | -99% |
| 5% | -99% |
Want more companies with a valuation profile/forecast similar to that of Neogenomics Inc? See ALC, AMPH, ARA, CSII, and ELAN.
Top Stories View All
Best & Worst Performing Stock Industries for March 31, 2020
Best & Worst Performing Small Cap Stocks for March 31, 2020
Best & Worst Performing Mid Cap Stocks for March 31, 2020
Best & Worst Performing Large Cap Stocks for March 31, 2020
Best & Worst Performing Mega Cap Stocks for March 31, 2020
View All Top Stories
Loading social stream, please wait...